On October 28, BRAINAURORA-B rose 12.13% in Regular Trading, trading at HK$1.385, with turnover of HK$73.72 million.
The move followed the company’s announcement that its cognitive function assessment software for patients with depression received a Class II medical device registration certificate from the Beijing municipal regulator.
The approved product, model BJHZ-NACT, is a standalone software tool designed to quantify memory, attention, executive function and information processing speed, and to generate assessment results for clinical decision-making. The company said the approval strengthens its digital medical product portfolio for cognitive disorders and helps reinforce its first-mover position in cognitive assessment for psychiatric conditions. This also comes after the company had previously indicated the product was expected to obtain registration around November, making the approval a concrete regulatory milestone.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments